Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis

References

• Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: molecules to medicine. J Clin Invest 2006;116(7):1744–54.
   PubMed Web of Science ®Google Scholar
• Scarrott JM, Herranz-Martin S, Alrafiah AR, et al. Current developments in gene therapy for amyotrophic lateral sclerosis. Expert Opin Biol Ther 2015;15(7):935–47.
   PubMed Web of Science ®Google Scholar
• de Lau LM, Breteler MM. Epidemiology of Parkinson's disease. Lancet Neurol 2006;5(6):525–35.
   PubMed Web of Science ®Google Scholar
• Prevalence of amyotrophic lateral sclerosis – United States, 2010–2011. Am J Public Health 2015;105(6):e7–9.
   Web of Science ®Google Scholar
• Collins SM, Surette M, Bercik P. The interplay between the intestinal microbiota and the brain. Nat Rev Microbiol 2012;10(11):735–42.
   PubMed Web of Science ®Google Scholar
• Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 2012;13(10):701–12.
   PubMed Web of Science ®Google Scholar
• Mayer EA, Tillisch K, Gupta A. Gut/brain axis and the microbiota. J Clin Invest 2015;125(3):926–38.
   PubMed Web of Science ®Google Scholar
• Sampson TR, Mazmanian SK. Control of brain development, function, and behavior by the microbiome. Cell Host Microbe 2015;17(5):565–576.
   PubMed Web of Science ®Google Scholar
• Catanzaro R, Anzalone M, Calabrese F, et al. The gut microbiota and its correlations with the central nervous system disorders. Panminerva Med 2015;57(3):127–43.
   PubMed Web of Science ®Google Scholar
• Friedland RP. Mechanisms of molecular mimicry involving the microbiota in neurodegeneration. J Alzheimers Dis 2015;45(2):349–62.
   PubMed Web of Science ®Google Scholar
• Naseer MI, Bibi F, Alqahtani MH, et al. Role of gut microbiota in obesity, type 2 diabetes and Alzheimer's disease. CNS Neurol Disord Drug Targets 2014;13(2):305–11.
   PubMed Web of Science ®Google Scholar
• Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysaccharides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev 2010;31(6):817–44.
   PubMed Web of Science ®Google Scholar
• Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature 2011;473(7346):174–80.
   PubMed Web of Science ®Google Scholar
• Aziz Q, Dore J, Emmanuel A, et al. Gut microbiota and gastrointestinal health: current concepts and future directions. Neurogastroenterol Motil 2013;25(1):4–15.
   PubMed Web of Science ®Google Scholar
• Sommer F, Backhed F. The gut microbiota–masters of host development and physiology. Nat Rev Microbiol 2013;11(4):227–38.
   PubMed Web of Science ®Google Scholar
• Gu S, Chen D, Zhang JN, et al. Bacterial community mapping of the mouse gastrointestinal tract. PLOS One 2013;8(10):e74957.
   PubMed Web of Science ®Google Scholar
• Maurice CF, Cl KS, Ladau J, et al. Marked seasonal variation in the wild mouse gut microbiota. ISME J 2015. doi:10.1038/ismej.2015.53.
   PubMed Web of Science ®Google Scholar
• Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature 2012;489(7415):220–30.
   PubMed Web of Science ®Google Scholar
• Holmqvist S, Chutna O, Bousset L, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathol 2014;128(6):805–20.
   PubMed Web of Science ®Google Scholar
• Goldman SM, Kamel F, Ross GW, et al. Peptidoglycan recognition protein genes and risk of Parkinson's disease. Mov Disord 2014;29(9):1171–80.
   PubMed Web of Science ®Google Scholar
• Gabrielli M, Bonazzi P, Scarpellini E, et al. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. Mov Disord 2011;26(5):889–92.
   PubMed Web of Science ®Google Scholar
• Tan AH, Mahadeva S, Thalha AM, et al. Small intestinal bacterial overgrowth in Parkinson's disease. Parkinsonism Relat Disord 2014;20(5):535–40.
   PubMed Web of Science ®Google Scholar
• Dobbs RJ, Charlett A, Dobbs SM, et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut Pathog 2012;4(1):12. doi: 10.1186/1757-4749-4-12
   PubMed Web of Science ®Google Scholar
• Cassani E, Barichella M, Cancello R, et al. Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease. Parkinsonism Relat Disord 2015;21(4):389–93.
   PubMed Web of Science ®Google Scholar
• Scheperjans F, Aho V, Pereira PA, et al. Gut microbiota are related to Parkinson's disease and clinical phenotype. Mov Disord 2015;30(3):350–8
   PubMed Web of Science ®Google Scholar
• Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol 2012;9(6):312–22.
   PubMed Web of Science ®Google Scholar
• Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLOS One 2011;6(12):e28032.
   PubMed Web of Science ®Google Scholar
• Kelly LP, Carvey PM, Keshavarzian A, et al. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Mov Disord 2014;29(8):999–1009.
   PubMed Web of Science ®Google Scholar
• Dobbs RJ, Dobbs SM, Weller C, et al. Role of chronic infection and inflammation in the gastrointestinal tract in the etiology and pathogenesis of idiopathic parkinsonism. Part 1: eradication of Helicobacter in the cachexia of idiopathic parkinsonism. Helicobacter 2005;10(4):267–75.
   PubMed Web of Science ®Google Scholar
• Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol 2008;130(1):55–70.
   PubMed Web of Science ®Google Scholar
• Natividad JM, Verdu EF. Modulation of intestinal barrier by intestinal microbiota: pathological and therapeutic implications. Pharmacol Res 2013;69(1):42–51.
   PubMed Web of Science ®Google Scholar
• Clairembault T, Leclair-Visonneau L, Coron E, et al. Structural alterations of the intestinal epithelial barrier in Parkinson's disease. Acta Neuropathol Commun 2015;3:12. doi: 10.1186/s40478-015-0196-0
   PubMed Web of Science ®Google Scholar
• Forsyth CB, Shannon KM, Kordower JH, et al. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLOS One 2011;6(12):e28032.
   PubMed Web of Science ®Google Scholar
• Guo S, Al-Sadi R, Said HM, Ma TY. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol 2013;182(2):375–87.
   PubMed Web of Science ®Google Scholar
• Dutta G, Zhang P, Liu B. The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008;22(5):453–64.
   PubMed Web of Science ®Google Scholar
• Tufekci KU, Genc S, Genc K. The endotoxin-induced neuroinflammation model of Parkinson's disease. Parkinsons Dis 2011;2011:487450.
   PubMed Web of Science ®Google Scholar
• Mafra D, Fouque D. Gut microbiota and inflammation in chronic kidney disease patients. Clin Kidney J 2015;8(3):332–4.
   PubMedGoogle Scholar
• Rodes L, Khan A, Paul A, et al. Effect of probiotics Lactobacillus and Bifidobacterium on gut-derived lipopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol 2013;23(4):518–26.
   PubMed Web of Science ®Google Scholar
• Letiembre M, Liu Y, Walter S, et al. Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol Aging 2009;30(5):759–68.
   PubMed Web of Science ®Google Scholar
• Ros-Bernal F, Hunot S, Herrero MT, et al. Microglial glucocorticoid receptors play a pivotal role in regulating dopaminergic neurodegeneration in parkinsonism. Proc Natl Acad Sci USA 2011;108(16):6632–7.
   PubMed Web of Science ®Google Scholar
• Noelker C, Morel L, Lescot T, et al. Toll like receptor 4 mediates cell death in a mouse MPTP model of Parkinson disease. Sci Rep 2013;3:1393. doi: 10.1038/srep01393
   PubMed Web of Science ®Google Scholar
• Ghosh A, Roy A, Liu X, et al. Selective inhibition of NF-kappaB activation prevents dopaminergic neuronal loss in a mouse model of Parkinson's disease. Proc Natl Acad Sci USA 2007;104(47):18754–9.
   PubMed Web of Science ®Google Scholar
• Charlett A, Dobbs RJ, Purkiss AG, et al. Cortisol is higher in parkinsonism and associated with gait deficit. Acta Neurol Scand. 1998;97(2):77–85.
   PubMed Web of Science ®Google Scholar
• Dobbs RJ, Charlett A, Purkiss AG, et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand. 1999;100(1):34–41.
   PubMed Web of Science ®Google Scholar
• Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun. 2009;23(1):55–63.
   PubMed Web of Science ®Google Scholar
• Chen H, O'Reilly EJ, Schwarzschild MA, Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol. 2008;167(1):90–5.
   PubMed Web of Science ®Google Scholar
• Rite I, Machado A, Cano J, Venero JL. Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. J Neurochem 2007;101(6):1567–82.
   PubMed Web of Science ®Google Scholar
• Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol 2005;57(2):176–9.
   PubMed Web of Science ®Google Scholar
• Zhao C, Ling Z, Newman MB, et al. TNF-alpha knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiol Dis 2007;26(1):36–46.
   PubMed Web of Science ®Google Scholar
• Chen X, Lan X, Roche I, et al. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem 2008;107(4):1147–57.
   PubMed Web of Science ®Google Scholar
• Pisani V, Stefani A, Pierantozzi M, et al. Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. J Neuroinflammation 2012;9:188. doi: 10.1186/1742-2094-9-188
   PubMed Web of Science ®Google Scholar
• Chung YC, Kim YS, Bok E, et al. MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease. Mediators Inflamm 2013;2013:370526.
   PubMed Web of Science ®Google Scholar
• Wu XL, Wang P, Liu YH, Xue YX. Effects of poly (ADP-ribose) polymerase inhibitor 3-aminobenzamide on blood-brain barrier and dopaminergic neurons of rats with lipopolysaccharide-induced Parkinson's disease. J Mol Neurosci 2014;53(1):1–9.
   PubMed Web of Science ®Google Scholar
• Gray MT, Woulfe JM. Striatal blood-brain barrier permeability in Parkinson's disease. J Cereb Blood Flow Metab 2015;35(5):747–50.
   PubMed Web of Science ®Google Scholar
• Hsu YT, Liao CC, Chang SN, et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriatr Psychiatry 2015;23(9):934–40.
   PubMed Web of Science ®Google Scholar
• Tong Q, Zhang L, Yuan Y, et al. Reduced plasma serotonin and 5-hydroxyindoleacetic acid levels in Parkinson's disease are associated with nonmotor symptoms. Parkinsonism Relat Disord 2015;21(8):882–7.
   PubMed Web of Science ®Google Scholar
• Maes M, Kubera M, Leunis JC. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29(1):117–24.
   PubMed Web of Science ®Google Scholar
• Yano JM, Yu K, Donaldson GP, et al. Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis. Cell 2015;161(2):264–76.
   PubMed Web of Science ®Google Scholar
• Jost WH. Gastrointestinal dysfunction in Parkinson's Disease. J Neurol Sci 2010;289(1–2):69–73.
   PubMed Web of Science ®Google Scholar
• Anitha M, Vijay-Kumar M, Sitaraman SV, et al. Gut microbial products regulate murine gastrointestinal motility via Toll-like receptor 4 signaling. Gastroenterology 2012;143(4):1006–16.e4.
   PubMed Web of Science ®Google Scholar
• Cassani E, Privitera G, Pezzoli G, et al. Use of probiotics for the treatment of constipation in Parkinson's disease patients. Minerva Gastroenterol Dietol 2011;57(2):117–21.
   PubMedGoogle Scholar
• Zakostelska Z, Kverka M, Klimesova K, et al. Lysate of probiotic Lactobacillus casei DN-114 001 ameliorates colitis by strengthening the gut barrier function and changing the gut microenvironment. PLOS One 2011;6(11):e27961.
   PubMed Web of Science ®Google Scholar
• Aoki T, Asahara T, Matsumoto K, et al. Effects of the continuous intake of a milk drink containing Lactobacillus casei strain Shirota on abdominal symptoms, fecal microbiota, and metabolites in gastrectomized subjects. Scand J Gastroenterol 2014;49(5):552–63.
   PubMed Web of Science ®Google Scholar
• Conlon MA, Bird AR. The impact of diet and lifestyle on gut microbiota and human health. Nutrients 2015;7(1):17–44.
   Web of Science ®Google Scholar
• Seidl SE, Santiago JA, Bilyk H, Potashkin JA. The emerging role of nutrition in Parkinson's disease. Front Aging Neurosci 2014;6:36. doi: 10.3389/fnagi.2014.00036
   PubMed Web of Science ®Google Scholar
• Cassani E, Barichella M, Cancello R, et al. Increased urinary indoxyl sulfate (indican): new insights into gut dysbiosis in Parkinson's disease. Parkinsonism Relat Disord 2015;21(4):389–93.
   PubMed Web of Science ®Google Scholar
• Zhang P, Tian B. Metabolic syndrome: an important risk factor for Parkinson's disease. Oxid Med Cell Longev 2014;2014:729194. doi: 10.1155/2014/729194
   PubMed Web of Science ®Google Scholar
• Palacios N, Gao X, McCullough ML, et al. Obesity, diabetes, and risk of Parkinson's disease. Mov Disord 2011;26(12):2253–9.
   PubMed Web of Science ®Google Scholar
• Chen J, Guan Z, Wang L, et al. Meta-analysis: overweight, obesity, and Parkinson's disease. Int J Endocrinol 2014;2014:203930.
   PubMed Web of Science ®Google Scholar
• Choi JY, Jang EH, Park CS, Kang JH. Enhanced susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in high-fat diet-induced obesity. Free Radic Biol Med 2005;38(6):806–16.
   PubMed Web of Science ®Google Scholar
• Morris JK, Bomhoff GL, Stanford JA, Geiger PC. Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 2010;299(4):R1082–90.
   PubMed Web of Science ®Google Scholar
• Cookson MR. Lardy brains make Parkinson's disease mice worse. J Neurochem 2014;131(6):697–8.
   PubMed Web of Science ®Google Scholar
• Rotermund C, Truckenmuller FM, Schell H, Kahle PJ. Diet-induced obesity accelerates the onset of terminal phenotypes in alpha-synuclein transgenic mice. J Neurochem 2014;131(6):848–58.
   PubMed Web of Science ®Google Scholar
• Daniel H, Moghaddas GA, Berry D, et al. High-fat diet alters gut microbiota physiology in mice. ISME J 2014;8(2):295–308.
   PubMed Web of Science ®Google Scholar
• Chen X, Lan X, Roche I, et al. Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. J Neurochem 2008;107(4):1147–57.
   PubMed Web of Science ®Google Scholar
• Machado-Filho JA, Correia AO, Montenegro AB, et al. Caffeine neuroprotective effects on 6-OHDA-lesioned rats are mediated by several factors, including pro-inflammatory cytokines and histone deacetylase inhibitions. Behav Brain Res 2014;264:116–25.
   PubMed Web of Science ®Google Scholar
• Cowan TE, Palmnas MS, Yang J, et al. Chronic coffee consumption in the diet-induced obese rat: impact on gut microbiota and serum metabolomics. J Nutr Biochem 2014;25(4):489–95.
   PubMed Web of Science ®Google Scholar
• Jaquet M, Rochat I, Moulin J, et al. Impact of coffee consumption on the gut microbiota: a human volunteer study. Int J Food Microbiol 2009;130(2):117–21.
   PubMed Web of Science ®Google Scholar
• Wang H, Zhao JX, Hu N, et al. Side-stream smoking reduces intestinal inflammation and increases expression of tight junction proteins. World J Gastroenterol 2012;18(18):2180–7.
   PubMed Web of Science ®Google Scholar
• Derkinderen P, Shannon KM, Brundin P. Gut feelings about smoking and coffee in Parkinson's disease. Mov Disord 2014;29(8):976–9.
   PubMed Web of Science ®Google Scholar
• Toepfer M, Schroeder M, Klauser A, et al. Delayed colonic transit times in amyotrophic lateral sclerosis assessed with radio-opaque markers. Eur J Med Res 1997;2(11):473–6.
   PubMedGoogle Scholar
• Toepfer M, Folwaczny C, Klauser A, et al. Gastrointestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 1999;1(1):15–9.
   PubMed Web of Science ®Google Scholar
• Toepfer M, Folwaczny C, Lochmuller H, et al. Noninvasive (13)C-octanoic acid breath test shows delayed gastric emptying in patients with amyotrophic lateral sclerosis. Digestion 1999;60(6):567–71.
   PubMed Web of Science ®Google Scholar
• Herdewyn S, Cirillo C, Van Den Bosch L, et al. Prevention of intestinal obstruction reveals progressive neurodegeneration in mutant TDP-43 (A315T) mice Mol Neurodegener 2014;9:24. doi: 10.1186/1750-1326-9-24
   PubMed Web of Science ®Google Scholar
• Nubling GS, Mie E, Bauer RM, et al. Increased prevalence of bladder and intestinal dysfunction in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 2014;15(3–4):174–9.
   PubMed Web of Science ®Google Scholar
• Wu S, Yi J, Zhang YG, et al. Leaky intestine and impaired microbiome in an amyotrophic lateral sclerosis mouse model. Physiol Rep 2015;3(4) :e12356. doi:10.14814/phy2.12356.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Lu Y, Fang X, et al. An astrocyte regenerative response from vimentin-containing cells in the spinal cord of amyotrophic lateral sclerosis's disease-like transgenic (G93A SOD1) mice. Neurodegener Dis 2015;15(1):1–12.
   PubMed Web of Science ®Google Scholar
• Nguyen MD, D'Aigle T, Gowing G, et al. Exacerbation of motor neuron disease by chronic stimulation of innate immunity in a mouse model of amyotrophic lateral sclerosis.J Neurosci 2004;24(6):1340–9.
   PubMed Web of Science ®Google Scholar
• Zhang R, Miller RG, Gascon R, et al. Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS). J Neuroimmunol 2009;206(1–2):121–4.
   PubMed Web of Science ®Google Scholar
• Longstreth WT Jr, Meschke JS, Davidson SK, et al. Hypothesis: a motor neuron toxin produced by a clostridial species residing in gut causes ALS. Med Hypotheses 2005;64(6):1153–6.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Hachiya NS. Hypothesis: gut as source of motor neuron toxin in the development of ALS. Med Hypotheses 2006;66(2):438–9.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Haller E, Saporta S, et al. Ultrastructure of blood-brain barrier and blood-spinal cord barrier in SOD1 mice modeling ALS. Brain Res 2007;1157:126–37.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Saporta S, Haller E, et al. Evidence of compromised blood-spinal cord barrier in early and late symptomatic SOD1 mice modeling ALS. PLOS One 2007;2(11):e1205.
   PubMed Web of Science ®Google Scholar
• Henkel JS, Beers DR, Wen S, et al. Decreased mRNA expression of tight junction proteins in lumbar spinal cords of patients with ALS. Neurology 2009;72(18):1614–6.
   PubMed Web of Science ®Google Scholar
• Nicaise C, Mitrecic D, Demetter P, et al. Impaired blood-brain and blood-spinal cord barriers in mutant SOD1-linked ALS rat. Brain Res 2009;1301:152–62.
   PubMed Web of Science ®Google Scholar
• Winkler EA, Sengillo JD, Sagare AP, et al. Blood-spinal cord barrier disruption contributes to early motor-neuron degeneration in ALS-model mice. Proc Natl Acad Sci USA 2014;111(11):E1035–42.
   PubMed Web of Science ®Google Scholar
• Husebye E, Hellstrom PM, Sundler F, et al. Influence of microbial species on small intestinal myoelectric activity and transit in germ-free rats. Am J Physiol Gastrointest Liver Physiol 2001;280(3):G368–80.
   PubMed Web of Science ®Google Scholar
• Choi CH, Chang SK. Alteration of gut microbiota and efficacy of probiotics in functional constipation. J Neurogastroenterol Motil 2015;21(1):4–7.
   PubMed Web of Science ®Google Scholar
• Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol 2011;10(12):1108–18.
   PubMed Web of Science ®Google Scholar
• Garbuzova-Davis S, Sanberg PR. Blood-CNS barrier impairment in ALS patients versus an animal model. Front Cell Neurosci 2014;8:21. doi: 10.3389/fncel.2014.00021
   PubMed Web of Science ®Google Scholar
• Greene JG. Animal models of gastrointestinal problems in Parkinson's disease. J Parkinsons Dis 2011;1(2):137–49.
   PubMedGoogle Scholar